Ars Pharmaceuticals, INC 10-Q quarterly reports

ARS Pharmaceuticals' Q2 2026 filing shows a substantial increase in revenue driven by neffy sales, but also highlights significant increases in operating expenses and ongoing legal challenges.

ARS Pharmaceuticals announced a significant increase in total revenue for the first quarter of 2026, driven by strong product sales of neffy and contributions from collaboration and supply agreements.

ARS Pharmaceuticals reports a significant increase in neffy product revenue and secured a $100 million term loan, but also saw a substantial rise in net loss and operating expenses for Q3 2025.

ARS Pharmaceuticals reports significant revenue growth from its needle-free epinephrine product, neffy, following its U.S. and EU commercial launches, despite increased operating losses due to aggressive market expansion.

ARS Pharmaceuticals reports its first quarter 2025 financial results, highlighting the ongoing commercial launch of Neffy and providing updates on regulatory and clinical developments.

ARS Pharmaceuticals has filed an amendment to its quarterly report to disclose changes in Rule 10b5-1 trading plans by an executive officer and a board member.

ARS Pharmaceuticals initiated the commercial launch of Neffy in the U.S. and secured a significant European partnership with ALK, while reporting a net loss of $41.9 million for the first nine months of 2024.

ARS Pharmaceuticals reported its second quarter 2024 financial results, highlighting progress towards potential regulatory approval for its lead product candidate, neffy.

ARS Pharmaceuticals reports a net loss of $10.3 million for Q1 2024, with a continued focus on obtaining regulatory approval for its lead product candidate, neffy.